Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells 36,256 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 36,256 shares of Alphatec stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $11.42, for a total value of $414,043.52. Following the transaction, the executive vice president now directly owns 735,074 shares in the company, valued at approximately $8,394,545.08. This trade represents a 4.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Sponsel also recently made the following trade(s):

• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total value of $2,380.00.

Alphatec Trading Up 5.9 %

Shares of ATEC stock traded up $0.68 during trading hours on Tuesday, hitting $12.14. 1,708,966 shares of the company were exchanged, compared to its average volume of 1,845,308. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $17.34. The firm has a fifty day moving average of $10.15 and a 200 day moving average of $8.07. The firm has a market cap of $1.72 billion, a PE ratio of -9.48 and a beta of 1.43. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Hedge Funds Weigh In On Alphatec

Hedge funds have recently made changes to their positions in the stock. Atria Investments Inc raised its position in shares of Alphatec by 8.0% in the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after buying an additional 1,460 shares during the period. Rhumbline Advisers lifted its stake in shares of Alphatec by 1.3% in the 4th quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company’s stock valued at $1,277,000 after purchasing an additional 1,746 shares in the last quarter. Entropy Technologies LP grew its holdings in shares of Alphatec by 14.9% during the 3rd quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company’s stock worth $120,000 after purchasing an additional 2,800 shares during the period. R Squared Ltd purchased a new position in Alphatec in the fourth quarter valued at approximately $29,000. Finally, Wrapmanager Inc. grew its stake in Alphatec by 9.5% during the third quarter. Wrapmanager Inc. now owns 38,399 shares of the medical technology company’s stock worth $213,000 after buying an additional 3,325 shares during the period. Institutional investors and hedge funds own 66.35% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on ATEC. Barclays upped their target price on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. Needham & Company LLC raised their price objective on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.